Skip to content

Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension

Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04753840
Enrollment
90
Registered
2021-02-15
Start date
2021-07-03
Completion date
2030-12-01
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.

Detailed description

A total of 200 patients with mild hypertension were enrolled in this study, using the method of open label and parallel grouping; 100 cases in the experimental group and 100 cases in the control group, The experimental group was divided into life intervention + drug group and life intervention + ripc group, with 50 patients in each group. The results of 24-hour ambulatory blood pressure monitoring (ABPM) of the three groups were observed before and 3 months after use, including HR, pulse pressure, 24-hour systolic blood pressure, 24-hour diastolic blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, nighttime systolic blood pressure and nighttime diastolic blood pressure. The changes of renalase, catecholamine, renin, angiotensin - Ⅱ, aldosterone, RhoA kinase, no, adenosine and bradykinin were observed.

Interventions

One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic

OTHERremote ischemic preconditioning(RIPC)

40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.

BEHAVIORALlifestyle intervention

Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.

Sponsors

Henan Institute of Cardiovascular Epidemiology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed patients with mild hypertension (SBP: 140\ 159mmHg; DBP: 90\ 99mmHg)

Exclusion criteria

* Cannot tolerate RIPC * Non-essential hypertension * patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance * patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.

Design outcomes

Primary

MeasureTime frameDescription
Mean systolic blood pressure3 months24-hour Mean systolic blood pressure measured by Ambulatory blood pressure monitoring
Mean diastolic blood pressure3 months24-hour Mean diastolic blood pressure measured by Ambulatory blood pressure monitoring

Secondary

MeasureTime frameDescription
Concentration of adenosine3 monthsblood adenosine concentration
Concentration of Renalase3 monthsblood renalase concentration
Concentration of renin3 monthsblood renin concentration
Concentration of bradykinin3 monthsblood bradykinin concentration
Concentration of catecholamine3 monthsBlood catecholamine concentration

Countries

China

Contacts

Primary ContactEn Li
1799077212@qq.com13525070525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026